The compound AMN107 has been shown to be more effective than Gleevec for the first-line treatment of chronic myelogenous leukemia (CML) according to recent data from researchers at the Dana-Farber Cancer Institute and scientists at Novartis AG in Switzerland. Researchers involved in the study were aiming to find a comparable drug to Gleevec for the treatment of CML, but one that targeted more of the cancer cells. According to a recent article in Cancer, AMN107 is 20 times more potent than Gleevec. Lead author Dr. James Griffin of the Dana-Farber Cancer Institute said, "While?approximately 95% of patients treated with Gleevec achieve remission, there clearly is a need for therapies that produce longer remissions, are active against advanced disease, and can be used when Gleevec loses effectiveness."
Ms. Farley is a freelance medical writer based in Wakefield, RI.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs